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Reverse immunodynamics: a new 
method for identifying targets of 
protective immunity
Katrina J. spensley1, paul s. Wikramaratna2, Bridget s. penman5, Andrew Walker3, 
Adrian L. smith3, oliver G. pybus3, Létitia Jean4, sunetra Gupta3 & José Lourenço  3
Despite a dramatic increase in our ability to catalogue variation among pathogen genomes, we 
have made far fewer advances in using this information to identify targets of protective immunity. 
epidemiological models predict that strong immune selection can cause antigenic variants to structure 
into genetically discordant sets of antigenic types (e.g. serotypes). A corollary of this theory is that 
targets of immunity may be identified by searching for non-overlapping associations of amino acids 
among co-circulating antigenic variants. We propose a novel population genetics methodology that 
combines such predictions with phylogenetic analyses to identify genetic loci (epitopes) under strong 
immune selection. We apply this concept to the AMA-1 protein of the malaria parasite Plasmodium 
falciparum and find evidence of epitopes among certain regions of low variability which could render 
them ideal vaccine candidates. The proposed method can be applied to a myriad of multi-strain 
pathogens for which vast amounts of genetic data has been collected in recent years.
Among pathogens for which protective immune responses are directed against conserved targets (epitopes), a 
single infection ensures lifelong immunity, and the goal of vaccination is to elicit natural-like immunity against 
such conserved targets. Most infectious diseases against which we have effective vaccines fall into this category 
(e.g. measles). By contrast, the primary targets of protective immunity in several important pathogens such as 
Plasmodium falciparum, the human immunodeficiency virus (HIV) or the influenza A virus, are highly diverse 
and present a challenge to the development of vaccines.
One solution to this problem that is currently being explored by several research groups, is the artificial boost-
ing of immunity towards conserved regions that are not sufficiently naturally immunogenic to prevent further 
infection upon single exposure1,2. Another solution is to target naturally immunogenic epitopes of very high var-
iability (e.g. influenza A), with the drawback that vaccines may need recurrent updating. As opposed to targeting 
conserved epitopes of low immunogenicity or highly variable epitopes of high immunogenicity, an alternative and 
less researched strategy is to target epitopes of limited variability which are under immune selection. This strat-
egy may allow to develop multi-allelic vaccines in which immunogenic epitopes that confer protection against a 
sub-population of strains are combined to provide broad coverage (e.g. Thompson et al.3).
In this study, we attempt to identify low variability epitopes under strong immune selection by using a novel 
approach based on the predictions of a multi-locus mathematical framework of pathogen evolution commonly 
referred to as strain theory4–6. The central premise we focus on, is that regions (or epitopes) under strong immune 
pressure are selected to self-organise into genetically discordant sets of antigenic types (e.g. dengue virus, menin-
gococcal or pneumococcal serotypes).
This prediction is so far supported by empirical observations within a variety of host-pathogen systems7–13. 
In our proposed approach, we invert this prediction to search for signatures of immune selection by identifying 
genetic regions which exhibit a high degree of non-overlap, but critically excluding those that may have arisen 
as a consequence of shared ancestry or due to structural interactions. We term this novel approach the reverse 
immunodynamic method and present proof of concept results from a vast number of genetic sequences of the 
apical membrane antigen 1 protein (AMA-1).
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AMA-1 is a trans-membrane protein common to all Plasmodium species with a putative role in invasion 
at erythrocytic and pre-erythrocytic stages of the parasite life-cycle. Antibodies to AMA-1 appear to inhibit 
erythrocyte invasion and are thus thought to play a role in clinical protection against both P. falciparum14–20, 
P. knowlesi21 and P. vivax22. Cellular responses to AMA-1 may provide immunity against both erythrocytic23 
and pre-erythrocytic forms of P. falciparum24. The potential of AMA-1 as a component of a multi-stage malaria 
vaccine is compromised by the polymorphism of many of the targets of natural immunity25,26 as well as by diffi-
culties in inducing lasting immune responses through vaccination27–30. The extracellular region of AMA-1 can 
be structurally resolved into three domains: DI, DII and DIII. The highest level of polymorphism is seen among 
residues in DI and DIII surrounding a conserved hydrophobic trough31–36 which plays a vital role in the inva-
sion process37–39. Antibodies against this region have been shown to block invasion in a strain-specific manner; 
however, it is also clear that these antibodies constitute only a small proportion of the total inhibitory humoral 
response26,40,41. Identifying low variability regions of AMA-1 that are under strong immune selection would afford 
the possibility of focusing vaccine-induced immune responses on these regions and ensure full coverage of vari-
ability at these critical epitopes.
Previous studies on AMA-1 genetic data have demonstrated that selection pressure as measured by standard 
population genetics measures is strongest within DI and DIII34–36, and that while these are also highly variable, 
they contain a number of less variable residues35,36. Using our proposed reverse immunodynamics method we 
expand on these studies by detecting strong signatures of non-overlap among a small number of dimorphic resi-
dues in DIII, thus identifying epitopes within that wide region which are targets of protective immunity.
Results
We implemented the reverse immunodynamic method by performing pairwise comparisons of all sites among 
1198 unique PfAMA-1 sequences obtained from GenBank, to determine whether any of these pairs exhib-
ited non-overlapping associations between amino acid residues (see Methods section for details). We used an 
Information Theory statistic known as Mutual Information (MI), scaled to its maximum value (scaled MI), to 
measure the degree of non-overlap in amino acid combinations between pairs of sites of PfAMA-1 sequences (see 
Supplementary Text 1 for mathematical formulations and theoretical background). The main results are focused 
on dimorphic sites as we aim at the discovery of low variability epitopes, but output of our approach for all poly-
morphic pairs of sites is made available in Table S1.
A limited number of site-pairs exhibit high non-overlap. Most pairs of sites showed low non-overlap, 
with only 10 pairs exhibiting a scaled MI in excess of 0.312 (Table 1), a threshold based on the top 1% of the dis-
tribution of all observed scaled MI values (upper limit of a stringent 98% confidence interval, CI) (Table S2). Of 
these pairs, 404/405, 448/451 and 283/285 were eliminated on grounds of sequence proximity based on the lower 
limit (d = 3) 95% CI of all observed distances between dimorphic pairs. Figure 1A highlights the remaining 7 
pairs among all the background scaled MI measures.
For most pairs, high non-overlap is unlikely to have arisen by neutral evolutionary processes. 
To assess whether high non-overlap between sites could have arisen by neutral evolutionary processes (e.g. ances-
try), we started by estimating a maximum likelihood (ML) phylogenetic tree from the sequences (see Methods 
for details). A major difference became evident upon inspection of the phylogenetic allelic structure of site-pair 
Association Amino Acid Combinations Scaled MI
496 vs 503
IN IR MN MR
0.89
602 3 14 561
503 vs 512
NK NR RK RR
0.61
565 52 40 524
451 vs 485
KI KK MI MK
0.57
604 103 15 476
496 vs 512
IK IR MK MR
0.53
552 68 54 523
283 vs 285
LE LQ SE SQ
0.52
242 71 1 883
439 vs 451
HK HM NK NM
0.5
660 72 46 390
206 vs 225
EI EN KI KN
0.5
96 806 290 6
439 vs 485
HI HK NI NK
0.41
588 144 30 406
448 vs 451
DK DM NK NM
0.39
705 196 2 295
404 vs 405
RE RK TE TK
0.34
108 635 367 84
Table 1. Counts of amino acid associations between pairs of sites with high non-overlap (scaled MI > 0.312).
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206/225 compared to the other pairs of interest (Fig. 2A). As is visually shown, the dominant non-overlapping 
pairs of amino acids at 206/225 are highly segregated and present an ancient dimorphic relationship, which has 
been observed in other P. falciparum genes such as DBLMSP/DBLMSP233, MSP142, or MSP243. The other pairs of 
sites exhibited a more interdigitated pattern, indicating multiple independent changes.
To try to quantify these differences, we calculated the parsimony score (PS) for each site (see Supplementary 
Text 1 for details), which is the minimum number of genetic changes required to explain the observed ancestral 
relationships (in this case, back and forth between the two possible amino acids at each site). We then calculated 
the product of scaled MI and the geometric mean of PS (GMPS) for each site, which we termed the S-score. 
Importantly, this new measure was found to preserve the same order as the scaled MI scores of the 7 pairs of 
interest (Table 1), except in the case of the 206/225 (values in Table S2). This meant that six out of seven pairs of 
sites had both intermediate-to-high scaled MI and GMPS values.
To obtain a null distribution of the S-score for hypothesis testing, we simulated 1000 sets of sequences which 
were (a) consistent with the ancestry of the empirical phylogenetic tree, and (b) had the same PS score at each 
dimorphic site as the empirical data (see Methods). Given that six out of seven pairs of sites of interest had the 
highest empirical S-scores, we selected, from each of the 1000 simulations, the highest S-scored pair of sites 
(termed rank 1 pairs, values in Table S4). The two-dimensional distribution of rank 1 pairs of sites (Fig. 2B, grey 
points) showed that neutral evolution can generate sites with high PS or high scaled MI values, but is unlikely to 
generate pairs of sites with both measures being high. When the site pairs of interest (Table 1) were overlaid on 
this null distribution, they could be seen to present both high scaled MI and PS values (red points) as expected 
from their high S-scores, except for pair 206/225 (green point).
From both the phylogenetic allelic structures (Fig. 2A) and the S-score rank 1 distribution (Fig. 2B), we con-
cluded that six out of the seven site-pairs of interest were unlikely to have arisen by neutral evolutionary processes 
(496/503, 503/512, 451/485, 496/512, 439/451, 439/485). Even when looking at the distributions of rank 1 to 6 
(Table S4), these pairs were found significantly outside their own simulated distributions (Fig. S8). In contrast, we 
were unable to reach the same conclusion for site-pair 206/225.
Physical proximity may explain some of the non-overlap. Some of the pairs of sites which scored 
most highly on S-score and scaled MI comprised 496, 503 and 512. However, mapping these onto the tertiary 
structure of AMA-1 (Fig. 3) shows that they are in very close proximity of each other and therefore we were 
unable to exclude biochemical interactions as the primary cause of this striking association. It is still possible that 
variation at these sites is held in strong non-overlap through immune selection. Antibodies specific to epitopes 
containing amino acids I/N/K may cross-react with all other epitopic variants except those containing M/R/R, 
thereby promoting the co-circulation of these non-overlapping combinations of residues at these sites; however, 
because of their structural adjacency, it is impossible to privilege this explanation over intrinsic steric advantages 
to these combinations.
Other highly scored pairs included sites 439, 451, and 485, which were sufficiently far enough apart in the 
tertiary structure to represent potential examples of immune selection forcing non-structurally related residues to 
co-segregate into discordant sets. We cannot, of course, completely eliminate long-range physical interactions as 
a cause of these associations, and whether it is indeed immune selection that is responsible for these patterns can 
only be established by functional studies. There should be no fundamental structural impediment to the existence 
Figure 1. Degree of non-overlap between amino acid residues at pairs of dimorphic sites. Each site on the 
x-axis (positions 149–534) that is dimorphic is compared with all other dimorphic sites. Those with high 
scores above a stringent scaled MI threshold are shown by bars spanning both sites (red and green). Scaled MI 
threshold is based on the top 1% of observed scaled MI values (CI 98% of the observed distribution, upper limit 
of 0.312, horizontal dotted grey line). Red bars mark pairs of sites of interest, and the green bar marks the pair 
that is not of interest once phylogenetic relationships are taken into account.
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of intermediate forms since they do occur at low frequencies, but whether they are disadvantaged due to lower 
intrinsic fitness or immune-mediated selection remains to be resolved by further experimental work.
Non-overlapping associations are also observed at the level of local populations. We also inves-
tigated the associations between sites 439, 451 and 485 on a smaller geographical scale to confirm that these pat-
terns did not arise due to certain combinations of alleles dominating by chance in particular areas. In all countries 
studied, both of the major sequence variant associations were present, with the secondary variants present at a 
lower frequency (Table 2). In particular, the dataset of 660 unique sequences from Mali showed high non-overlap 
for each pair. A smaller dataset comprising 79 sequences from the Gambia also yielded scaled MI values in excess 
of those obtained from the global data set. Slightly weaker associations were found in 86 unique sequences from 
Kenya. However, these were seen to improve significantly when the data were analysed as a collection of isolates 
rather than sequences: i.e. without excluding identical sequences present in different individuals (Table 3).
As the model predictions pertain to population level frequencies of allele combinations, rather than their 
presence in a collection of unique sequences, we believe that Table 3 presents a more valid test (than when only 
unique sequences are included) of the model’s capabilities to pick out regions under strong immune selection. 
Figure 2. Empirical phylogenetic allelic structure, simulated parsimony score and scaled MI. (A) Example, 
ML phylogenetic trees of AMA-1 with branches coloured on the basis of observed combination of amino 
acid variants found at tips for different pairs of sites. Pink and cyan are used for the two most common amino 
acid variants (which are discordant for these sites, see Table 1) and black for the least common. (B) Empirical 
pairs of sites described in Fig. 1 and Table 1 are shown in relation to a null distribution of site-pairs from 1000 
simulations that scored most highly (rank 1) on S-score (the product of scaled MI measuring non-overlap, and 
geometric mean of parsimony score indicating the minimum number of genetic changes required to explain 
the observed ancestral relationships, GMPS). Color key (scale) on the right is the two-dimensional density of 
GMPS and scaled MI of the simulated site-pairs. (A,B) Pairs of sites identified in red and green in the two panels 
match the pairs in Fig. 1.
Figure 3. Surface representation of the crystal structure of AMA-1 with specific sites highlighted. The 
highlighted amino acids are the same in both panels and the ones relevant and described in Table 1 and Figs 1 
and 2. The right panel is a 90 degree rotation of the left panel, in which Lys 512 and Met 496 are revealed. Amino 
acids are the consensus of all sequences.
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It is nonetheless reassuring that these patterns are also evident under the more stringent conditions where only 
unique sequences are included.
Discussion
In this study, we have set out to demonstrate reverse immunodynamics, a new population genetics approach that 
is able to identify targets of immune selection under the theoretical expectations of a well established, multi-locus 
framework of pathogen evolution. Our results suggest that DIII of AMA-1 contains several epitopes of lower vari-
ability that are under strong immune selection. These epitopes may play an important role in protective immunity 
alongside more polymorphic epitopes in the C1L region of DI which have so far compromised the development 
of an effective vaccine.
The identification of possible epitopes in DIII follows the conclusions of several studies based on standard 
population genetics (sPG) techniques that strongly indicate that DIII is under selection34–36,44–47. However, sPG 
such as Tajima’s D are generally applied to windows of amino acids, and have critically not been devised for, and 
do not have the theoretical ground to identify immunity as the source of selection48,49. Reverse immunodynamics 
complements sPG techniques by finely mapping loci, which are tentatively under immune pressure within regions 
known to be under selection (through sPG analyses, as is the case of DIII).
Much work has also been done previously on AMA-1 site-pairs using measures of linkage disequilibrium 
(LD) such as D or R-squared (e.g.34–36), demonstrating that the alleles of many pairs are less mixed than expected 
by random chance (even in the presence of high recombination rates). Typically, such signatures can be used to 
infer that selection pressure has structured alleles into non-random associations. While it is tempting to assume 
that site-pairs high on LD are also high on MI, this is not necessarily true. The key difference is that MI is both 
a measure of linkage and non-overlap, while LD ignores the latter (for empirical and theoretical demonstration 
see Supplementary Text 1). We set on to look for signatures of non-overlap as these are critically predicted to be 
driven by strong immune selection, and therefore LD was not suited for the analyses. Finally, AMA-1 is known 
to present high recombination potential34–36, giving rise to a wide range of haplotypes35. According to complex 
transmission models based on strain theory, non-overlap is still a self-emergent signature among antigenic loci 
even in the presence of high recombination rates50.
So far, the evidence that DIII elicits protective antibody responses is limited, but much research supports this 
possibility. For instance, at a functional level, DIII has been shown to bind to the erythrocyte membrane protein 
Kx51, and immune responses that interrupt this process may, therefore, have a significant inhibitory effect on 
parasite growth. Nair et al.52 have also shown that antibodies from a single blood donor affinity purified on DIII 
are inhibitory. In a study by Polley et al.15, it was found that antibody responses against recombinant full-length 
ectodomains were more strongly associated with protection than responses to those which did not express DIII, 
even though naturally acquired antibodies to recombinant DIII alone were rare. A virosomal formulation of 
Association Country and Amino Acid Combinations Scaled MI
439 vs 451
HK HM NK NM
Gambia 46 3 0 31 0.701
Kenya 46 3 9 27 0.402
Mali 395 25 11 211 0.637
HI HK NI NK
439 vs 485
Gambia 39 7 1 30 0.549
Kenya 45 4 1 35 0.682
Mali 359 61 17 205 0.453
451 vs 485
KI KK MI MK
Gambia 39 4 1 35 0.673
Kenya 46 9 0 31 0.515
Mali 366 40 10 244 0.608
Table 2. Country-specific counts of amino acid associations between positions 439, 451 and 485 within unique 
sequences obtained from The Gambia, Kenya and Mali.
Association Amino Acid Combinations Scaled MI
439 vs 451
HK HM NK NM
0.564
61 3 9 55
439 vs 485
HI HK NI NK
0.772
60 4 1 63
451 vs 485
KI KK MI MK
0.644
61 9 0 59
Table 3. Counts of amino acid associations between positions 439, 451 and 485 in a population study (duplicate 
sequences not excluded) in Kilifi, Kenya.
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loop I of DIII, comprising residues 446–490, has also been shown to elicit growth-inhibitory antibodies53 and 
volunteers within a vaccine trial containing this AMA-1 peptide exhibited both reduced blood stage growth 
rates and a higher rate of morphological parasite abnormalities54. A recent analysis of allele-specific efficacy 
of a vaccine against AMA-125 showed that the relative risk ratio (RRR) of re-infection with strains containing 
vaccine-type amino acids among vaccinees vs controls was high (although not significant) at residues 439, 451 
and 485. Interestingly, in the same study, the likelihood of a shift from a vaccine- to non-vaccine type residue 
among sequences obtained following vaccination was found to be significantly increased at position 485 and 
non-significantly increased at position 451.
An interesting feature of our analyses is that while particular groups of sites exhibit strong non-overlap, the 
associations between these groups appear to be random. For example, the triad 439–451–485 is in complete 
linkage equilibrium with triad 496–503–512. Furthermore, there are no non-overlapping associations present 
between the highly polymorphic residues in the C1L region of Domain I and the 439–451–485 triad (although 
the former exhibit strong non-overlap, Table S1). If our analyses are correct, then it would be sufficient to present 
the dominant non-overlapping variants of 439–451–485 (i.e. HKI and NMK) in a manner that induced strong 
immune responses to the epitopes containing these residues, rather than to try and cover the entire haplotypic 
diversity of AMA-155. Immune responses to the epitopes containing residues 439, 451 and 485 appear to develop 
more slowly under natural conditions than antibodies to the highly polymorphic regions shielding the hydro-
phobic groove15 but should be easier to induce by vaccination than immune responses to completely conserved 
epitopes56.
Following theoretical expectations, our analyses emphasize that targets of natural immunity are not neces-
sarily polarised between the completely invariant and the highly polymorphic, but also critically include a range 
of epitopes of intermediate variability that have so far been largely overlooked3. The reverse immunodynamics 
method introduced in this study has the potential to identify and direct research towards such targets. While the 
method is likely to evolve with its application to other datasets, we foresee that its future use will help solve the 
impasse reached in vaccine discovery and development of many multi-strain pathogens.
Methods
Genetic sequence selection. PfAMA-1 sequences were obtained by searching the NCBI Entrez nucleotide 
and protein databases. This yielded 2835 protein sequences and 2926 nucleotide sequences (up to and including 
year 2014). In cases when the GenBank nucleotide record did not include the corresponding protein sequence, 
these were translated using Biopython57 (v1.69).
The analysis was restricted to sequences between 400 and 622 amino acids in length. The lower limit aims 
to ensure that all the polymorphic regions across the three domains are included; the upper limit corresponds 
to the entire processed protein, and therefore removes any entries which contain the non-coding sequence. To 
avoid pseudoduplication, all identical sequences were removed, leaving 1198 unique sequences. These were then 
aligned using ClustalW58 (Clustal2, v2.1).
Indels and other undetermined states. We first truncated our protein alignment to the region where we 
had >99% coverage. The resulting sequence alignment (from residue 149 to residue 534) had only 0.0025% of 
gaps (state ‘−’) and 0.0138% of undetermined amino acids (state ‘X’). In our analysis, we ignored all variants that 
had gap or undetermined alleles.
Measuring non-overlap among dimorphic sites. A frequency analysis of all residues within the 
three domains was used to identify any polymorphic sites. Only variants with a frequency exceeding 2.5% were 
included in the subsequent analysis. This identified 44 dimorphic sites (Fig. S1). We searched for signatures of 
immune selection by analysing the mutual information (MI) scores of all pairs of sites (Table S1).
Geographic sub-analysis. We repeated the calculation of MI for all isolates whose country of origin could 
be identified (either from the Entrez database or with reference to published papers).
phylogenetic analysis. The alignment was used to construct a maximum likelihood (ML) tree using 
Mega659 under the JTT model (with also: 4 discrete categories of gamma-distributed rates among sites; the 
nearest-neighbour-interchange heuristic; and a very strong branch swap filter). The resulting ML tree was used 
to calculate the maximum parsimony score (PS) for each dimorphic site (Fig. S2; Table S1). PS was calculated 
using the Phangorn R-package60 (v2.3.1) function parsimony with default options. We defined a new measure 
herein termed S-score, as the product of the MI and the geometric mean of the PS for each site (values available 
in Table S2). We used Seq-Gen61 (v1.3.4) to simulate 1000 sets of protein sequences with the same phylogenetic 
characteristics, restricting variation at each of the sites to two amino acids.
tertiary structures. From the protein data bank (PDB) the sequences and tertiary structures of Plasmodium 
vivax AMA-1 (PvAMA-1, PDB 1W81) and PfAMA-1 domain III (PDB 1HN6) were downloaded. As the tertiary 
structure of 1HN6 was mostly unstructured, it could not be used on its own. Therefore a Fold and Function 
Assignment System (FFAS) was used to align the amino acid sequences of 1W81 and 1HN6. From this align-
ment a ‘hybrid’ structural model with 94% confidence was generated using SCWRL. This resulting model gave a 
single tertiary structure with the residues within domain III from PvAMA-1 (1W81) substituted by those from 
PfAMA-1 (1HN6) using the P. vivax structural coordinates. Pymol (http://www.pymol.org/) was used to visualise 
the ‘hybrid’ tertiary structure and to highlight the relevant residues.
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